NCT06212583View on ClinicalTrials.gov

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Prostate CancerOligometastatic Disease
Interventions
DRUG

niraparib/abiraterone acetate

Patients on Arm 2 to receive drug for 6 months

RADIATION

Stereotactic ablative radiation therapy (SABR)

Both arms will receive SABR

DRUG

Androgen deprivation therapy (ADT)

All ADT is provided as best prescribed for patient per their medical oncologist.

Trial Locations (1)

21201

RECRUITING

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of Maryland, Baltimore

OTHER